About the study
This Phase 2 dose finding study is evaluating GSK5784283, an investigational anti-TSLP antibody, in adults aged 18 to 75 with uncontrolled asthma despite standard inhaled therapy. This study is currently active, with no new participants being enrolled.
Who can participate
You may be eligible if you:
- Are 18–75 years old
- Have a diagnosis of asthma that remains uncontrolled on current therapy
- Are currently on a daily controller inhaler
This study is active but not currently recruiting. Contact us to be considered for future studies in this program.
What to expect
- Lung function testing and symptom assessments at each visit
- Investigational study drug provided at no cost
- Compensation for time and travel